Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the ...

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone.

A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective compound, and carvedilol, a widely used cardiovascular medicine—to powerfully ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

By recreating a fetal liver niche, FLOs show how liver and immune cells co-develop. Learn more about new groundbreaking research ...

December 8, 2025—Delcath Systems, Inc. announced the publication of a retrospective study reporting outcomes from patients with liver-dominant metastatic uveal melanoma (mUM) treated with Delcath’s ...

2 Liver Fibrosis Research Unit, Department of Community Health, Tokai University School of Medicine, Isehara, Japan 3 Department of Anatomy & Neurobiology, Graduate School of Medicine, Osaka City ...

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.

Melphalan/HDS efficacious, has favorable risk-benefit profile for unresectable metastatic uveal melanoma. HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the ...